Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Title:
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Author:
Clemens, Michael R. Gladkov, Oleg A. Gartner, Elaina Vladimirov, Vladimir Crown, John Steinberg, Joyce Jie, Fei Keating, Anne